Under the High Patronage of His Excellency the Minister of ... · Speakers: Ahmad Ibrahim, MD - Walid Moukaddem,, MD Chairs: Rita Assi, MD - Hanane Yassine, MD • Abstract 7000:

Organized by The Lebanese Society of Medical OncologyLicensed by The American Society of Clinical Oncology

July 12 - 13, 2019 | Hilton Beirut Habtoor Grand - Lebanon

www.lsmo-lb.org

Under the High Patronage of His Excellencythe Minister of Public Health

Dr. Jamil Jabak

14th

July 12 - 13, 2019 | Hilton Beirut Habtoor Grand - Lebanon July 12 - 13, 2019 | Hilton Beirut Habtoor Grand - Lebanon

Dear Colleagues,It gives me great pleasure to welcome you to “The 14th Annual Best of ASCO meeting 2019” organized by the Lebanese Society of Medical Oncology LSMO under the license of ASCO, which will be held on July 12-13 , 2019 at Hilton Beirut Habtoor Hotel, Beirut - Lebanon.

This year’s congress will feature up-to-date information on several topics in the field of Oncology and malignant hematology. The congress will bring together several experts in the field and will be widely attended, locally and regionally.

We expect to host over 300 oncology physicians, highly renowned speakers who will cover a wide range of exciting and timely topics in the different disciplines of Oncology, and host attendees coming from all over the Middle East, Europe, and the United States. As usual, and as per ASCO regulations, the Planning Committee included the most relevant abstracts selected by ASCO’s Best of ASCO committee and in addition to two Education Sessions.

Your participation and support are essential where only here you can customize a unique educational experience, selected from an unparalleled array of topics, learning styles, and expert viewpoints. Best of ASCO 2019 will provide a good networking venue for people to get to know each other better and the experiences you share with colleagues, your challenging questions for our presenters and your dedication to our mission all contribute to an outstanding event.

I wish you all a productive meeting and memorable time in Lebanon.

Nizar Bitar, MD Nagi El Saghir, MDChair of the Best of ASCO Co-Chair of the Best of ASCO


14th Best of ASCO LebanonJuly 12-13 , 2019 | Hilton Beirut Habtoor Hotel, Beirut - Lebanon Organized by LSMO (Lebanese Society of Medical Oncology)Licensed by ASCO (American Society of Clinical Oncology)

Chairs:Nizar Bitar, MD ChairNagi El Saghir, MD, FACP, FASCO Co-Chair

Planning Committee:Nizar Bitar, MDNagi El Saghir, MD, FACP, FASCOJoseph Makdessi, MDRoger Khater, MDHazem Assi, MDJoseph Kattan, MD

Organizing Committee / LSMO Board

Nizar Bitar, MD PresidentRoger Khater, MD President ElectOussama Jradi, MD General SecretaryTherese Abou Nasr, MD TreasurerNaji Amro, MD MemberMohammad Haidar, MD MemberWalid Moukadem, MD MemberRita Murr, MD MemberHanane Yassine, MD Member


Guest Speaker

Ahmad Awada, MD Ahmad Ibrahim, MD Antoine Fenianos, MDArafat Tfayli, MD Caroline Semaha, MD David Atallah, MD Deborah Mukherji, MD Eileen O'Reilly, MD Fadi El Karak, MD Fadi Nasr , MDFadlo Khuri, MD Fares Azouri, MD Francois Kamar, MD Georges Chahine, MD Georges Farha, MD Ghassan Abou Alfa , MDGhazi Nsouli, MD Hampig Kourie, MD Hazem Assi, MD Jad Wakim, MDJoseph Kattan, MD Joseph Makdessi, MD Khaled Ibrahim, MD Marcel Massoud, MD Muhieddine Seoud, MD Nabil Chamseddine, MD Nagi El Saghir, MD Nizar Bitar, MD Rabih Said, MD Roger Khater, MD Sally Tamraz, MD Sanaa Al SukhunTherese Abi Nasr, MDWalid Moukaddem, MDWassim Mchayleh, MD Ziad Salem, MD

BelgiumLebanonLebanonLebanonLebanonLebanonLebanonUSALebanonLebanonLebanonLebanonLebanonLebanonLebanonUSALebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonLebanonJordanLebanonLebanonLebanonLebanon


Friday July 12, 201908:00 REGISTRATION

09:00 - 09:45 Lung Cancer | Non-Small Cell Local-Regional / Small Cell / Thoracic CancersSpeakers: Arafat Tfayli, MD - Fadi El Karak, MD

Chairs: Hassan Ghazal, MD - Adnan Atallah, MD• Abstract 8503: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).(David J. Kwiatkowski, MD, PhD) Presented by Arafat Tfayli, MD

• Abstract 8504: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.(Tina Cascone, MD, PhD) Presented by Arafat Tfayli, MD

• Abstract 8506: Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.(Luis G. Paz-Ares, MD, PhD) Presented by Fadi El Karak, MD

09:45 - 10:30 Lung Cancer | Non-Small Cell MetastaticSpeaker: Fadlo Khuri, MDChairs: Nizar Bitar, MD - Roger Khater, MD• Abstract 9000: RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).(Kazuhiko Nakagawa, MD, PhD) Presented by Fadlo Khuri, MD

• Abstract 9001: Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).(Vanita Noronha) Presented by Fadlo Khuri, MD

• Abstract 9002: ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.(Suresh S. Ramalingam, MD) Presented by Fadlo Khuri, MD

10:30 - 10:50 Coffee Break


Friday July 12, 201910:50 - 11:30 Gastrointestinal Cancers | Gastrointestinal (Colorectal) CancerSpeakers: Sally Tamraz, MD - Ghassan Abou Alfa, MD - Eileen O’reilly, MDChairs: Clemence Matta, MD - Nizar Bitar, MD - Oussama Safar, MD• Abstract 3501: Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).(Timothy Iveson, MD, FRCP) Presented by Sally Tamraz, MD

• Abstract 3504: FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.(Matthew T. Seymour, MD) Presented by Ghassan Abou Alfa, MD

• Abstract 3508: Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.(Chiara Cremolini, MD) Presented by Eileen O’Reilly, MD

11:30 - 12:30 Gastrointestinal Cancers | Gastrointestinal (Noncolorectal) CancerSpeakers: Eileen O’Reilly, MD - Ghassan Abou Alfa, MDChairs: Sally Tamraz, MD - Fadi Nasr, MD• Abstract LBA4: Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.(Hedy L. Kindler) Presented by Eileen O’Reilly, MD

• Abstract 4000: APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.(Margaret A. Tempero, MD, FASCO) Presented by Eileen O’Reilly, MD

• Abstract 4003: ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.(Angela Lamarca, MD, PhD) Presented by Ghassan Abou Alfa, MD

• Abstract LBA4007: Pembrolizumab with or without chemotherapy versus chemotherapy for advancedgastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase IIIKEYNOTE-062 study.(Josep Tabernero, MD, PhD) Presented by Ghassan Abou Alfa, MD


12:30 - 13:00 Opening CeremonyAddress of the President of Lebanese Society of Medical Oncologyand Chair of the Best of ASCONizar Bitar, MD

Address of the President of the Lebanese Order of Physicians - BeirutCharaf Abou Charaf, MD

Address of His Excellency, The Minsiter of Public HealthJamil Jabak, MD

13:00 - 14:00 Lunch Break

14:00 - 14:45 Head and Neck CancerSpeakers: Marcel Massoud, MD - Fadi El Karak, MD - Ziad Salem, MDChairs: Joseph Makdessi, MD - Rahif Jalloul, MD• Abstract 6000: Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(Danny Rischin) Presented by Marcel Massoud, MD

• Abstract 6002: TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(Joel Guigay, MD) Presented by Fadi El Karak, MD

• Abstract 6003: Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.(Jun Ma) Presented by Ziad Salem, MD

Friday July 12, 2019


Friday July 12, 201914:45 - 15:15 Hematologic Malignancies, Part I

Leukemia, Myelodysplastic Syndromes, and AllotransplantSpeakers: Ahmad Ibrahim, MD - Walid Moukaddem,, MDChairs: Rita Assi, MD - Hanane Yassine, MD • Abstract 7000: Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.(Mark J. Levis, MD, PhD) Presented by Ahmad Ibrahim, MD

• Abstract 7005: ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).(Timothy P. Hughes) Presented by Walid Moukaddem, MD

15:15 - 16:00 Hematologic Malignancies, Part ILymphoma and Chronic Lymphocytic Lymphoma

Speakers: Jad Wakim, MD - Khaled Ibrahim, MD - Fadi Nasr, MDChairs: Nidal Jomaa, MD - Haifa Dbouk, MD - Mona Ayoubi, MD• Abstract 7502: Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.(Kirsten Fischer, MD) Presented by Jad Wakim, MD

• Abstract 7506: Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.(Nathan Hale Fowler) Presented by Khaled Ibrahim, MD

• Abstract 7510: Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.(Paul M. Barr, MD) Presented by Fadi Nasr, MD


Friday July 12, 201916:00 - 16:20 Coffee Break

16:20 - 17:20 Hematologic Malignancies, Part II | Plasma Cell DyscrasiaSpeakers: Ahmad Ibrahim, MD - Khaled Ibrahim,MD - Nabil Chamseddine, MD Georges Chahine, MDChairs: Joseph Kattan, MD - Therese Abi Nasr, MD• Abstract 8001: E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.(Sagar Lonial, MD) Presented by Ahmad Ibrahim, MD

• Abstract 8004: A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).(Paul G. Richardson, MD) Presented by Khaled Ibrahim, MD

• Abstract 8005: Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.(Maria-Victoria Mateos, PhD) Presented by Nabil Chamseddine, MD

• Abstract 7507: Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study. (Pieternella J. Lugtenburg) Presented by Georges Chahine, MD

17:20 - 17:50 Symptoms and SurvivorshipSpeakers: Georges Chahine, MD - Ahmad Awada, MDChairs: Joseph Kattan, MD - Hassan Kanaan, MD• Abstract 11503: A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study. (Hironobu Hashimoto, BPharm) Presented by Georges Chahine, MD

• Abstract 11506: Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.(Matteo Lambertini, MD) Presented by Ahmad Awada, MD


Saturday July 13, 201909:00 - 09:45 Genitourinary Cancers, PART I | Genitourinary (Prostate) CancerSpeakers: Joseph Makdessi, MD - Nizar Bitar, MD Chairs: Riwa Sakr, MD - Abir Ahmadieh, MD• Abstract LBA2: Overall survival (OS) results of a phase III randomized trial of standard of care therapy with or without enzalutamide for metastatic hormone sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international co-operative group trial.(Christopher Sweeney) Presented by Joseph Makdessi, MD

• Abstract 5006: First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).(Kim N. Chi, MD, FRCPC) Presented by Nizar Bitar, MD

• Abstract 5008: Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). (Michael J. Morris, MD) Presented by Nizar Bitar, MD

09:45 - 10:45 Genitourinary Cancers, PART II | Genitourinary (NonProstate) CancerSpeakers: Deborah Mukherji, MD - Roger Khater, MD - Joseph Kattan, MDChairs: Evelyne Helou, MD - Layal Halabi, MD• Abstract 4500: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.(Brian I. Rini, MD, FACP) Presented by Deborah Mukherji, MD

• Abstract 4503: CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.(Jonathan E. Rosenberg, MD) Presented by Roger Khater, MD

• Abstract 4504: Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.(Matt D. Galsky, MD, FASCO) Presented by Joseph Kattan, MD

• Abstract 4505: EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. (Daniel Peter Petrylak, MD) Presented by Joseph Kattan, MD


Saturday July 13, 201910:45 - 11:05 Coffee Break

11:05 - 11:50 Breast Cancer | Local / Regional / AdjuvantSpeakers: Ahmad Awada, MD - Ghazi Nsouli, MD - Fares Azouri, MDChairs: Adel Tabchi, MD - Issam Chehade, MD• Abstract 503: Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. (Joseph A. Sparano, MD) Presented by Ahmad Awada, MD

• Abstract 504: Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).(Lucia Del Mastro, MD) Presented by Ghazi Nsouli, MD

• Abstract 508: Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.(Patricia A. Ganz, MD, FASCO) Presented by Fares Azouri, MD

11:50 - 12:50 Breast Cancer | MetastaticSpeakers: Nagi El Saghir, MD - Ahmad Awada, MD - Sanaa Al Sukhun, MD - Hazem Assi, MDChairs: Oussama Jradi, MD - Therese Abi Nasr, MD - Georges El Hachem, MD - Chritina Khater, MD• Abstract 1000: SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).(Hope S. Rugo, MD, FASCO) Presented by Nagi El Saghir, MD

• Abstract 1002: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.(Cristina Saura, MD, PhD) Presented by Ahmad Awada, MD

• Abstract 1003: IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).(Peter Schmid, MD, PhD, FCRP) Presented by Sanaa Al Sukhun, MD

• Abstract LBA1008: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.(Sara A. Hurvitz, MD) Presented by Hazem Assi, MD


Saturday July 13, 201912:50 - 13:35 SarcomaSpeakers: Hazem Assi, MD - Caroline Semaha, MD - Rabih Said, MDChairs: Mounif Ghaith, MD - Abdel Fattah Kheir, MD• Abstract LBA3: ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).(William D. Tap, MD) Presented by Hazem Assi, MD

• Abstract 11001: STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.(Sylvie Bonvalot, MD, PhD) Presented by Caroline Semaha, MD

• Abstract 11015: Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.(Melissa Amber Burgess, MD) Presented by Rabih Said, MD

13:35 - 14:30 Lunch Break

14:30 - 15:00 Central Nervous System Tumors Speakers: Hampig Kourie, MD - François Kamar, MDChairs: Ali Monzer, MD - Jawad Makarem, MD• Abstract 2000: Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.(Martin J. Van Den Bent, MD, PhD) Presented by Hampig Kourie, MD

• Abstract 2001: Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.(Carmen Balana, MD, PhD) Presented by François Kamar, MD


Saturday July 13, 201915:00 - 16:00 Gynecologic CancerSpeakers: David Atallah, MD - Muhieddine Seoud, MDChairs: Nadine Kassis, MD - Deborah Mukherji, MD• Abstract 5500: A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.(Matthew A. Powell, MD) Presented by David Atallah, MD

• Abstract 5505: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.(Mansoor Raza Mirza, MD) Presented by Muhieddine Seoud, MD

• Abstract 5506: Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.(Richard T. Penson, MD, MRCP) Presented by Muhieddine Seoud, MD

• Abstract 5508: EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.(Claire Falandry) Presented by David Atallah, MD


Saturday July 13, 201916:00 - 17:15 Melanoma/Skin CancersSpeakers: Antoine Fenianos - Georges Farha, MD - Therese Abi Nasr, MD Wassim Mchayleh, MD - Joseph Makdessi, MDChairs: Nizar Bitar, MD - Joseph Makdessi, MD• Abstract 2512: Ipilimumab versus placebo after complete resection of stage III melanoma:Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. (Alexander M. M. Eggermont, MD) Presented by Antoine Fenianos, MD

• Abstract 9500: Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).(Gerald Fogarty, MD) Presented by Georges Farha, MD

• Abstract 9501: Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).(Hussein Abdul-Hassan Tawbi, MD, PhD) Presented by Therese Abi Nasr, MD

• Abstract 9503: Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).(Alexander M. Menzies, MBBS, FRACP, PhD) Presented by Wassim Mchayleh, MD

• Abstract 9507: Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.(Paul D. Nathan, MD) Presented by Joseph Makdessi, MD

17:15 Adjourn

Organized by: 4th Floor, Qubic CenterDaoud Ammoun StreetHorsh Tabet - Sin El FilP.O. Box: 90-361 BeirutTel: +961 1 510880/1/2/3 Mobile: +961 71 103123

[email protected] | www.infomedweb.com

LEBANON UAE

|DMCC Business CentreAlmas TowerJumeirah Lakes Dubai, United Arab EmiratesUnit No: 3820Mobile: +971 50 9110475

Documents

Under the High Patronage of His Excellency the Minister of ... · Speakers: Ahmad Ibrahim, MD - Walid Moukaddem,, MD Chairs: Rita Assi, MD - Hanane Yassine, MD • Abstract 7000: